Login / Signup

Differences in the incidence of lurasidone adverse events between depressive disorders and schizophrenia in double-blind, randomized, placebo-controlled trials: a meta-analysis.

Taro KishiHiroshi NakamuraNakao Iwata
Published in: Psychopharmacology (2021)
The incidence of AEs did not differ between schizophrenia and depressive disorders.
Keyphrases
  • placebo controlled
  • bipolar disorder
  • double blind
  • phase iii
  • clinical trial
  • phase ii
  • risk factors
  • study protocol
  • phase ii study
  • stress induced
  • randomized controlled trial
  • open label
  • squamous cell carcinoma